Science & Enterprise subscription

Follow us on Twitter

  • Genny Cream for me, if I were there https://t.co/BQcWbr7yLh
    about 1 hour ago
  • As the race to produce and distribute Covid-19 vaccines intensifies, financing of this global public health project… https://t.co/pyDX0IWnCs
    about 7 hours ago
  • New post on Science and Enterprise: Infographic – Public Money Funds Covid-19 Vaccines https://t.co/1D2XLhUi4Z #Science #Business
    about 7 hours ago
  • Excellent analysis. Real example: a colleague I hired at Science mag is leaving her job to get a grad degree in IT. https://t.co/c0qnYW025H
    about 10 hours ago
  • Two biotechnology companies are collaborating on using the gene editing technique Crispr to create engineered immun… https://t.co/4lK4qD5p6m
    about 1 day ago

Please share Science & Enterprise

Multiple Organs Impaired in Long Covid-19 Patients

MRI scan of kidneys

A study of individuals with lingering symptoms from Covid-19 shows they experience impaired organ functions months after the initial infections. . . . → Read More: Multiple Organs Impaired in Long Covid-19 Patients

Trial Shows Malaria Vaccine Protects Young Children

Malaria clinic in Cameroon

Results from a clinical trial in Burkina Faso show a high efficacy rate for a candidate vaccine to protect young children against malaria infections. . . . → Read More: Trial Shows Malaria Vaccine Protects Young Children

Challenge Trial Testing Covid-19 Reinfection

SARS-Cov-2 virus

A clinical trial is underway testing immune responses from new Covid-19 infections in volunteers previously infected with the virus. . . . → Read More: Challenge Trial Testing Covid-19 Reinfection

Novavax Joins Alternative Second Shot Vaccine Trial

Syringes

Vaccine developer Novavax is taking part in a clinical trial testing effects of different Covid-19 vaccines in first and second immunizations. . . . → Read More: Novavax Joins Alternative Second Shot Vaccine Trial

Vaccine Spin-Off Raises $168 Million in New Funds

Syringes

A developer of vaccines, including a leading Covid-19 vaccine, and cancer immunotherapies, is raising $168 million in its second venture round. . . . → Read More: Vaccine Spin-Off Raises $168 Million in New Funds

Two Therapies Dropped from NIH Covid-19 Trial

SARS-CoV-2 and cell

A clinical trial testing multiple treatments for people hospitalized with Covid-19 infections is dropping two therapies for not meeting efficacy standards. . . . → Read More: Two Therapies Dropped from NIH Covid-19 Trial

New Trial Testing Reformulated Covid-19 Vaccine

Panama City skyline

Two drug makers are beginning a clinical trial to test their reformulated vaccine against Covid-19 disease, particularly among older populations. . . . → Read More: New Trial Testing Reformulated Covid-19 Vaccine

New Funds Backing Global Health, Early-Stage Ventures

Stock market graphic

Three new funds are financing start-up companies creating solutions for health issues in less-developed countries and early-stage life science businesses. . . . → Read More: New Funds Backing Global Health, Early-Stage Ventures

Biotech, UK Govt to Design Covid-19 Variant Vaccines

Vaccine vials

A biotechnology company and a U.K. government agency agreed to quickly develop and produce vaccines to protect against emerging Covid-19 viral mutations. . . . → Read More: Biotech, UK Govt to Design Covid-19 Variant Vaccines

Cannabidiol Drug Maker Acquired in $7.2B Deal

Cannabis plant

A developer of treatments for rare neurological diseases derived from cannabis is being acquired by Jazz Pharmaceuticals in a $7.2 billion deal. . . . → Read More: Cannabidiol Drug Maker Acquired in $7.2B Deal